# REC-1245 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rec-1245

> REC-1245, sponsored by RECURSION PHARMACEUTICALS, INC. (RXRX): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | REC-1245 |
| Codes | REC-1245 |
| Sponsor | RECURSION PHARMACEUTICALS, INC. (RXRX) https://sec-api.dev/companies/rxrx/catalysts |
| Indications | unresectable locally advanced or metastatic cancer |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep 2024: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2025-02-28, last confirmed 2025-02-28.
- SEC Form 10-K (accession 0001601830-25-000035): "Following IND clearance in September 2024, we initiated a Phase 1/2 (DAHLIA) study in December 2024 to evaluate the safety, tolerability, PK/PD, and preliminary efficacy of REC-1245 in unresectable, locally advanced, or metastatic cancers." https://www.sec.gov/Archives/edgar/data/1601830/000160183025000035/rxrx-20241231.htm
- SEC Form 10-K (accession 0001601830-25-000035): "Following IND clearance in September 2024, we initiated a Phase 1/2 open-label, multicenter study (DAHLIA) to evaluate the safety, tolerability, PK, PD, RP2D, and preliminary efficacy of REC-1245." https://www.sec.gov/Archives/edgar/data/1601830/000160183025000035/rxrx-20241231.htm

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 1/2. Indication: unresectable locally advanced or metastatic cancer.
- First seen 2025-02-28, last confirmed 2026-02-25.
- SEC Form 10-K (accession 0001601830-26-000039): "In December 2024, we initiated a Phase 1/2 open-label, multicenter study to characterize the safety, tolerability, PK, PD, and preliminary anti-tumor activity of REC-1245 in participants with unresectable locally advanced or metastatic cancer." https://www.sec.gov/Archives/edgar/data/1601830/000160183026000039/rxrx-20251231.htm
- SEC Form 10-K (accession 0001601830-25-000035): "In December 2024, we initiated a Phase 1/2 open-label, multicenter study to characterize the safety, tolerability, PK, PD, and preliminary anti-tumor activity of REC-1245 in participants with unresectable locally advanced or metastatic cancer." https://www.sec.gov/Archives/edgar/data/1601830/000160183025000035/rxrx-20241231.htm
- SEC Form 10-K (accession 0001601830-25-000035): "With the first patient dosed in December 2024, we expect to share an update on the program in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1601830/000160183025000035/rxrx-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rec-1245.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "REC-1245 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rec-1245

```bibtex
@misc{secapidev_pdufa_rec_1245_20261116,
  title        = {REC-1245 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rec-1245}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rec_1245_20261116","title":"REC-1245 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rec-1245","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
